LONG
BEACH, Calif., Aug. 2, 2024
/PRNewswire/ -- Anivive Lifesciences Inc, a One Health technology
company today announced that the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of
Health, has awarded Anivive a new contract (#75N93024C00009) worth
up to $33M to support the development
of a vaccine against the fungus Coccidioides, which causes
Valley Fever.
... holds potential to be the first vaccine
to prevent a serious systemic fungal infection common to humans and
animals.
Contract funding aims to utilize the underlying science in
Anivive's animal health Valley Fever vaccine for dogs, currently
under review by USDA Center for Veterinary Biologics, to develop a
similar vaccine for humans. The funding will address IND-enabling
activities, including additional manufacturing, formulation,
extensive safety testing, and an IND submission, before then
completing a human Phase 1 clinical trial.
Rising temperatures and extreme weather are setting the stage
for increases in fungal diseases. Recognizing the growing global
public health problem, in 2022, the World Health Organization (WHO)
released its first-ever list of fungal "priority pathogens,"
calling for policy improvements and research in such areas as
fungal disease distribution, patterns of antifungal resistance, and
who is most at risk of exposure and disease. Currently, there are
no antifungal vaccines approved for human or animal use.
"Anivive is honored to receive this NIAID contract, which will
greatly accelerate our efforts to commercialize a vaccine to
protect people against Valley Fever," said Dr. Edward Robb, Anivive Lifesciences Chief Strategy
Officer and Principal Investigator. "This collaborative effort has
delivered a significant step forward in the field of vaccinology
and holds the potential to be the first vaccine to prevent a
serious systemic fungal infection common to humans and animals,"
said Robb.
Anivive has built a strong research team to catalyze this
breakthrough and deliver a first-in-class solution for an emerging
fungal disease. Additionally, this program is supported by: Valley
Fever Center for Excellence at the University
of Arizona College of Medicine for the non-clinical
development, Recipharm for the contract manufacturing, Quigley
BioPharma for vaccine development support and Latham BioPharm
Group, part of Sia Partners for the program management, financial
compliance, quality assurance and additional technical subject
matter expertise.
About Anivive Lifesciences
Anivive is a pet pharmaceutical company at the intersection of
biotech, AI, software, and veterinary medicine. Our proprietary
software platform accelerates the development of new, affordable
diagnostics, treatments and preventatives for various
life-threatening diseases in pets. Anivive's pipeline includes 8+
first-in-class technologies for three critical areas: Oncology,
virology and infectious disease. Anivive is a privately held
company based in Long Beach,
California. Visit www.anivive.com to learn more.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing
Organization (CDMO) in the pharmaceutical industry employing over
7,000 employees. Recipharm offers manufacturing services of
pharmaceuticals and biologics in various dosage forms, production
of clinical trial material and APIs, pharmaceutical product
development and development and manufacturing of medical devices.
Recipharm manufactures several hundred different products for
customers ranging from big pharma to smaller research and
development companies. The company operates development and
manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered
in Stockholm, Sweden
About Quigley BioPharma LLC
Quigley BioPharma LLC (Quigley) is a Contract Product
Development Organization specializing in strategies to streamline
and accelerate advanced development of biological products for
prevention and treatment of infectious diseases, cancer and
allergies. Quigleys unique, industry-experienced,
multi-disciplinary development team with 10 successful product
launches offers a turnkey solution to public and private
biotechnology and pharmaceutical enterprises allowing flexibility
in resource allocation and enhanced return on investment.
About Latham BioPharm Group
Latham BioPharm Group (LBG) is a leading life science consulting
company that works with pharmaceutical, biotech, CROs, academia,
and medical device/diagnostic companies alike to solve complex
business, regulatory, and product development challenges.
About University of
Arizona Valley Fever Center for Excellence
The Arizona Board of Regents
established the UA Valley Fever Center for Excellence in 1996 for
the benefit of the entire state. Based at the UA Health Sciences
campus—which includes the UA College of Medicine – Tucson, College of Pharmacy, College of
Nursing and Mel and Enid Zuckerman
College of Public Health—the center has developed a research
base that includes the state's three universities, and an
information program for the scientific community and the general
public. Its work encompasses public awareness, clinical guidelines
and training, and research into rapid detection methods for the
disease as well as development of a vaccine for both animals and
humans.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anivive-receives-niaid-contract-worth-up-to-33m-to-progress-valley-fever-vaccine-302213741.html
SOURCE Anivive Lifesciences Inc.